Literature DB >> 12072417

Induction of thyroid hormone-degrading deiodinase in cardiac hypertrophy and failure.

Frank W J S Wassen1, Anja E Schiel, George G J M Kuiper, Ellen Kaptein, Onno Bakker, Theo J Visser, Warner S Simonides.   

Abstract

The similarities between the changes in cardiac gene expression in pathological ventricular hypertrophy and hypothyroidism suggest a role of impaired cardiac thyroid hormone (TH) action in the development of contractile dysfunction during chronic cardiac pressure overload. Here we studied the possible involvement of altered cardiac TH metabolism using a rat model of right-ventricular (RV) hypertrophy induced by pressure-overload. Pathological RV hypertrophy was indicated by decreased mRNA levels of sarcoplasmic reticulum(SR) Ca2-ATPase type 2a (SERCA2a) and myosin heavy chain a (MHCalpha), and increased levels of MHCbeta mRNA. Enzyme activity of type HI deiodinase (D3), which converts T4 and T3 to the inactive compounds rT3 and 3,3'-T2, respectively, was identified in ventricular tissue. This activity was stimulated up to five fold in hypertrophic RV, but remained unaltered in the non-hypertrophic left ventricle (LV). A low level of type Ideiodinase activity was also detected, which decreased significantly in both RV and LV. Stimulation of RV D3 activity was significantly higher in those animals in which hypertrophy progressed to heart failure, compared to animals that developed compensatory hypertrophy. The induction of a cardiac TR-degrading deiodinase maybe expected to result in reduced cellular levels of T3 and thereby contribute to a local hypothyroid state in the hypertrophic and, particularly, in the failing ventricle.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12072417     DOI: 10.1210/endo.143.7.8985

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  49 in total

1.  Absence of myocardial thyroid hormone inactivating deiodinase results in restrictive cardiomyopathy in mice.

Authors:  Cintia B Ueta; Behzad N Oskouei; Emerson L Olivares; Jose R Pinto; Mayrin M Correa; Gordana Simovic; Warner S Simonides; Joshua M Hare; Antonio C Bianco
Journal:  Mol Endocrinol       Date:  2012-03-08

2.  Association of serum triiodothyronine with B-type natriuretic peptide and severe left ventricular diastolic dysfunction in heart failure with preserved ejection fraction.

Authors:  Senthil Selvaraj; Irwin Klein; Sara Danzi; Nausheen Akhter; Robert O Bonow; Sanjiv J Shah
Journal:  Am J Cardiol       Date:  2012-04-11       Impact factor: 2.778

Review 3.  Atrophied cardiomyocytes and their potential for rescue and recovery of ventricular function.

Authors:  Mark R Heckle; David M Flatt; Yao Sun; Salvatore Mancarella; Tony N Marion; Ivan C Gerling; Karl T Weber
Journal:  Heart Fail Rev       Date:  2016-03       Impact factor: 4.214

Review 4.  Nonthyroidal illness and the cardiorenal syndrome.

Authors:  Christiaan L Meuwese; Olaf M Dekkers; Peter Stenvinkel; Friedo W Dekker; Juan J Carrero
Journal:  Nat Rev Nephrol       Date:  2013-09-03       Impact factor: 28.314

Review 5.  Reawakened interest in type III iodothyronine deiodinase in critical illness and injury.

Authors:  Stephen A Huang; Antonio C Bianco
Journal:  Nat Clin Pract Endocrinol Metab       Date:  2008-01-22

Review 6.  The role of thyroid hormone in the pathophysiology of heart failure: clinical evidence.

Authors:  E Galli; A Pingitore; G Iervasi
Journal:  Heart Fail Rev       Date:  2008-12-27       Impact factor: 4.214

7.  Deiodination and cellular proliferation: parallels between development, differentiation, tumorigenesis, and now regeneration.

Authors:  Stephen A Huang
Journal:  Endocrinology       Date:  2009-01       Impact factor: 4.736

Review 8.  Minireview: Defining the roles of the iodothyronine deiodinases: current concepts and challenges.

Authors:  Donald L St Germain; Valerie Anne Galton; Arturo Hernandez
Journal:  Endocrinology       Date:  2009-01-29       Impact factor: 4.736

Review 9.  Cellular and molecular basis of deiodinase-regulated thyroid hormone signaling.

Authors:  Balázs Gereben; Ann Marie Zavacki; Scott Ribich; Brian W Kim; Stephen A Huang; Warner S Simonides; Anikó Zeöld; Antonio C Bianco
Journal:  Endocr Rev       Date:  2008-09-24       Impact factor: 19.871

10.  Targeting iodothyronine deiodinases locally in the retina is a therapeutic strategy for retinal degeneration.

Authors:  Fan Yang; Hongwei Ma; Joshua Belcher; Michael R Butler; T Michael Redmond; Sanford L Boye; William W Hauswirth; Xi-Qin Ding
Journal:  FASEB J       Date:  2016-09-13       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.